Impairment of lymphocyte locomotion in the tumor microenvironment and the effect of systemic immunotherapy with liposome-encapsulated myramyl-tripeptide-phosphatidylethanolamine

Diana Risin, Eugenie S. Kleinerman, Yasuiki Umezu, Roland P. Pizzini, Charles M. Balch, Neal R. Pellis

Research output: Contribution to journalArticle

Abstract

The ability of the lymphocytes to move through the interstitium is obligatory to the immune response. We previously showed that tumor-infiltrating lymphocytes (TIL) from human melanoma and renal cell carcinoma demonstrate a dramatic decrease in their spontaneous locomotion through three-dimensional collagen gel when compared with peripheral blood lymphocytes (PBL) and lymph node lymphocytes. To determine if this decrease is caused by contact with tumor cells, or mediated through certain diffusible factors, we examined the effects of autologous tumor cells on the locomotion of PBL in a model system where tumor cells were separated from lymphocytes by a 3-mm layer of gelled collagen. After 21-22 h incubation in chamber slides, locomotion distances were assessed in the presence and absence of tumor and normal cells. In the presence of tumor cells. PBL from 14 of 18 patients displayed substantial (466.5±2.7 μm compared to control 568.9±10.9 μm, P

Original languageEnglish (US)
Pages (from-to)57-64
Number of pages8
JournalCancer Immunology Immunotherapy
Volume40
Issue number1
DOIs
StatePublished - Jan 1995
Externally publishedYes

Fingerprint

Tumor Microenvironment
Locomotion
Liposomes
Immunotherapy
Lymphocytes
Neoplasms
Collagen
Tumor-Infiltrating Lymphocytes
Renal Cell Carcinoma
Cell Movement
phosphatidylethanolamine
Melanoma
Lymph Nodes
Gels

Keywords

  • Immunotherapy MTP-PE
  • Locomotion TIL

ASJC Scopus subject areas

  • Oncology
  • Immunology
  • Cancer Research

Cite this

Impairment of lymphocyte locomotion in the tumor microenvironment and the effect of systemic immunotherapy with liposome-encapsulated myramyl-tripeptide-phosphatidylethanolamine. / Risin, Diana; Kleinerman, Eugenie S.; Umezu, Yasuiki; Pizzini, Roland P.; Balch, Charles M.; Pellis, Neal R.

In: Cancer Immunology Immunotherapy, Vol. 40, No. 1, 01.1995, p. 57-64.

Research output: Contribution to journalArticle

@article{56f52349e6804dc68e616d679db1b8b6,
title = "Impairment of lymphocyte locomotion in the tumor microenvironment and the effect of systemic immunotherapy with liposome-encapsulated myramyl-tripeptide-phosphatidylethanolamine",
abstract = "The ability of the lymphocytes to move through the interstitium is obligatory to the immune response. We previously showed that tumor-infiltrating lymphocytes (TIL) from human melanoma and renal cell carcinoma demonstrate a dramatic decrease in their spontaneous locomotion through three-dimensional collagen gel when compared with peripheral blood lymphocytes (PBL) and lymph node lymphocytes. To determine if this decrease is caused by contact with tumor cells, or mediated through certain diffusible factors, we examined the effects of autologous tumor cells on the locomotion of PBL in a model system where tumor cells were separated from lymphocytes by a 3-mm layer of gelled collagen. After 21-22 h incubation in chamber slides, locomotion distances were assessed in the presence and absence of tumor and normal cells. In the presence of tumor cells. PBL from 14 of 18 patients displayed substantial (466.5±2.7 μm compared to control 568.9±10.9 μm, P",
keywords = "Immunotherapy MTP-PE, Locomotion TIL",
author = "Diana Risin and Kleinerman, {Eugenie S.} and Yasuiki Umezu and Pizzini, {Roland P.} and Balch, {Charles M.} and Pellis, {Neal R.}",
year = "1995",
month = "1",
doi = "10.1007/BF01517236",
language = "English (US)",
volume = "40",
pages = "57--64",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "1",

}

TY - JOUR

T1 - Impairment of lymphocyte locomotion in the tumor microenvironment and the effect of systemic immunotherapy with liposome-encapsulated myramyl-tripeptide-phosphatidylethanolamine

AU - Risin, Diana

AU - Kleinerman, Eugenie S.

AU - Umezu, Yasuiki

AU - Pizzini, Roland P.

AU - Balch, Charles M.

AU - Pellis, Neal R.

PY - 1995/1

Y1 - 1995/1

N2 - The ability of the lymphocytes to move through the interstitium is obligatory to the immune response. We previously showed that tumor-infiltrating lymphocytes (TIL) from human melanoma and renal cell carcinoma demonstrate a dramatic decrease in their spontaneous locomotion through three-dimensional collagen gel when compared with peripheral blood lymphocytes (PBL) and lymph node lymphocytes. To determine if this decrease is caused by contact with tumor cells, or mediated through certain diffusible factors, we examined the effects of autologous tumor cells on the locomotion of PBL in a model system where tumor cells were separated from lymphocytes by a 3-mm layer of gelled collagen. After 21-22 h incubation in chamber slides, locomotion distances were assessed in the presence and absence of tumor and normal cells. In the presence of tumor cells. PBL from 14 of 18 patients displayed substantial (466.5±2.7 μm compared to control 568.9±10.9 μm, P

AB - The ability of the lymphocytes to move through the interstitium is obligatory to the immune response. We previously showed that tumor-infiltrating lymphocytes (TIL) from human melanoma and renal cell carcinoma demonstrate a dramatic decrease in their spontaneous locomotion through three-dimensional collagen gel when compared with peripheral blood lymphocytes (PBL) and lymph node lymphocytes. To determine if this decrease is caused by contact with tumor cells, or mediated through certain diffusible factors, we examined the effects of autologous tumor cells on the locomotion of PBL in a model system where tumor cells were separated from lymphocytes by a 3-mm layer of gelled collagen. After 21-22 h incubation in chamber slides, locomotion distances were assessed in the presence and absence of tumor and normal cells. In the presence of tumor cells. PBL from 14 of 18 patients displayed substantial (466.5±2.7 μm compared to control 568.9±10.9 μm, P

KW - Immunotherapy MTP-PE

KW - Locomotion TIL

UR - http://www.scopus.com/inward/record.url?scp=0028796259&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028796259&partnerID=8YFLogxK

U2 - 10.1007/BF01517236

DO - 10.1007/BF01517236

M3 - Article

C2 - 7828168

AN - SCOPUS:0028796259

VL - 40

SP - 57

EP - 64

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 1

ER -